Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAStem cell injection for acute exacerbation of interstitial lung disease
ChiCTR2400081256Phase 2Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Feb 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of CAStem cells in interstitial lung disease (ILD) (3 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Mortality at 3 months. Started Feb 2024; status: recruiting.
02
Drugs
CAStem cells
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR2400081256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081256.